News
Multimedia
Publication
Conferences
Resources
Subscribe
Webcasts

Spotlight -

Downstream Processing|

Upstream Processing

|Articles|April 15, 2013

Open Innovation: Transforming the Model of Biopharmaceutical R&D

Don Frail, Vice President, AstraZeneca Innovative Medicines Group discusses the company's approach to innovation and the upcoming session at the BIO International Convention

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Content

Parkinson's disease. 3D illustration showing neurons containing Lewy bodies small red spheres which are deposits of proteins (alpha-synuclein) accumulated in the brain cells. | Image credit: © Lars Neumann - © Lars Neumann - stock.abode.com

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

ByFeliza Mirasol

December 4th 2025

small interfering RNA bound to a messenger RNA, cartoon model with semi-transparent surface. siRNAs are synthetic RNA interference tools used for inducing temporary reduction of mRNA expression. | Image credit: © petarg - © petarg - stock.adobe.com

Emerging siRNA Platform Offers New Metabolic Disorder Therapies

ByFeliza Mirasol

December 3rd 2025

Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration

ByFeliza Mirasol

November 29th 2025

Antibody drug conjugate in blue with four drug compounds linked to IgG immunoglobulin; ADC in blue against blue background 3d render | Image credit: © huenstructurebio.com - © huenstructurebio.com - stock.adobe.com

How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment

ByFeliza Mirasol

November 25th 2025

Molecular model of antibody taking part in immune defense. Molecule of immunoglobulin, 3D illustration | Image credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com

What a $2 Billion Maryland Expansion Means for the Future of Biologics Production

ByFeliza Mirasol

November 24th 2025

Trending on BioPharm International

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models

Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

Implementing Automation and Flexible Design for Allogeneic Manufacturing

© 2025 MJH Life Sciences^®

All rights reserved.